Holen Sie sich die Stockscreener-App
1.99
6.57%
-0.14
Handel nachbörslich:
2.00
0.01
+0.50%
Schlusskurs vom Vortag:
$2.13
Offen:
$2.15
24-Stunden-Volumen:
118.38K
Relative Volume:
0.61
Marktkapitalisierung:
$6.85M
Einnahmen:
$895.50K
Nettoeinkommen (Verlust:
$-26.30M
KGV:
-1.2134
EPS:
-1.64
Netto-Cashflow:
$-23.84M
1W Leistung:
+0.51%
1M Leistung:
+39.16%
6M Leistung:
-55.78%
1J Leistung:
-86.94%
1-Tages-Spanne:
$1.8926
$2.15
1-Wochen-Bereich:
$1.775
$2.17
52-Wochen-Spanne:
$1.3381
$19.00
Mainz Biomed N V Stock (MYNZ) Company Profile
Firmenname
Mainz Biomed N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MYNZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
1.99 | 7.55M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Maxim Group | Buy |
| 2024-11-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Mainz Biomed N V Aktie (MYNZ) Neueste Nachrichten
When the Price of (MYNZ) Talks, People Listen - news.stocktradersdaily.com
What drives Mainz Biomed N.V. stock priceExceptional profit velocity - Autocar Professional
Is Mainz Biomed N.V. a good long term investmentDynamic portfolio growth - jammulinksnews.com
What analysts say about Mainz Biomed N.V. stockTremendous financial leverage - Autocar Professional
Mainz Biomed N.V. Stock Analysis and ForecastBreakthrough profits - Autocar Professional
Why Mainz Biomed N.V. stock attracts strong analyst attentionFree Long-Term Wealth Growth Plan - beatles.ru
Mainz Biomed (NASDAQ:MYNZ) Trading Up 7% – Here’s Why - Defense World
Mainz Biomed Half Year 2025 Update: Accelerating FDA - GlobeNewswire
What makes Mainz Biomed N.V. stock price move sharplyFree Stock Market Expert Consultation - Newser
ARBI(arbipad) News and UpdatesProtected Capital Trading Plan - Newser
How Mainz Biomed N.V. stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
Mainz Biomed reviews accomplishments for first half of 2025 - TipRanks
Mainz Biomed N.V. Announces Key Achievements and Corporate Update for First Half of 2025 - Nasdaq
Mainz Biomed's Dual Breakthrough: FDA Trial Progress and Revolutionary 95% Accurate Pancreatic Cancer Detection - Stock Titan
Mainz Biomed (MYNZ) Secures State Funding for Pancreatic Cancer Project | MYNZ Stock News - GuruFocus
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - FinancialContent
Mainz Biomed (MYNZ) to Release Quarterly Earnings on Tuesday - Defense World
Where are the Opportunities in (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Down 1.9% – Here’s What Happened - Defense World
(MYNZ) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Ca - GuruFocus
Mainz Biomed Initiates Feasibility Study Of PancAlert Blood Test For Pancreatic Cancer Detection - Nasdaq
Mainz Biomed Initiates Feasibility Study Of Biomarker Panel In Pancreatic Cancer Project - MarketScreener
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Cancer Detection | MYNZ Stock News - GuruFocus
Mainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert Project - Nasdaq
Mainz initiates feasibility study of biomarker panel in PancAlert project - TipRanks
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - The Manila Times
Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | M - GuruFocus
Mainz Biomed N.V. Secures $4 Million Through Securities Offering - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Trading Up 5.4% – What’s Next? - Defense World
Mainz Biomed (MYNZ) Prices $4M Follow-On Offering - GuruFocus
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - The Manila Times
Finanzdaten der Mainz Biomed N V-Aktie (MYNZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):